These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 31669398)
1. Late Events After CD-19 CAR-T Treatment. Hossain NM; Nishimura MI Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398 [No Abstract] [Full Text] [Related]
2. Trafficking of CAR T cells to sites of subclinical leukaemia cutis. O'Reilly M; Roddie C; Marzolini MAV; Rodriguez-Justo M; Pomplun S; Pule M; Peggs KS Lancet Oncol; 2020 Mar; 21(3):e179. PubMed ID: 32135121 [No Abstract] [Full Text] [Related]
3. CAR T-cells for relapsed B-cell ALL in adults. Gilbert JA Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915 [No Abstract] [Full Text] [Related]
4. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047 [No Abstract] [Full Text] [Related]
5. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Chow VA; Shadman M; Gopal AK Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Chow VA; Gopal AK; Maloney DG; Turtle CJ; Smith SD; Ujjani CS; Shadman M; Cassaday RD; Till BG; Tseng YD; Warren EH; Shustov AR; Menon MP; Bhark S; Acharya UH; Mullane E; Hannan LM; Voutsinas JM; Gooley TA; Lynch RC Am J Hematol; 2019 Aug; 94(8):E209-E213. PubMed ID: 31056762 [No Abstract] [Full Text] [Related]
7. CAR T-cells for relapsed B-cell ALL in children and young adults. Stirrups R Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913 [No Abstract] [Full Text] [Related]
8. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report. Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L Front Immunol; 2021; 12():728962. PubMed ID: 34691036 [TBL] [Abstract][Full Text] [Related]
9. Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia. Dourthe ME; Yakouben K; David A; Thouvenin S; Chaillou D; Caillat-Zucman S; Cuffel A; Tardy C; Lainey E; Caye-Eude A; Arfeuille C; Delaugerre C; Chaix-Baudier ML; Naudin J; Auvin S; Bergaoui K; Merlat-Guitard AI; De Jorna R; Mebarki M; Dalle JH; Baruchel A Br J Haematol; 2024 Jul; 205(1):373-377. PubMed ID: 38735758 [No Abstract] [Full Text] [Related]
10. Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy. Wang Y; Xue YJ; Zuo YX; Jia YP; Lu AD; Zeng HM; Zhang LP J Transl Med; 2024 Jul; 22(1):680. PubMed ID: 39061064 [No Abstract] [Full Text] [Related]
11. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832 [TBL] [Abstract][Full Text] [Related]
12. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]